Compare AREC & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AREC | GLSI |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.5M | 372.0M |
| IPO Year | N/A | 2020 |
| Metric | AREC | GLSI |
|---|---|---|
| Price | $3.14 | $28.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.50 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 3.3M | 168.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42,083.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $7.78 |
| 52 Week High | $7.11 | $34.10 |
| Indicator | AREC | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 55.34 |
| Support Level | $3.02 | $9.47 |
| Resistance Level | $3.30 | $32.61 |
| Average True Range (ATR) | 0.26 | 2.29 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 65.87 | 89.12 |
American Resources Corp constructs and/or purchases and manages a chain of combined gasoline, diesel and natural gas (NG) fueling and service stations; construct conversion factories to convert NG to liquefied natural gas (LNG) and compressed natural gas (CNG); and construct conversion factories to retrofit vehicles currently using gasoline or diesel fuel to also run on NG in the United States and also to build a convenience store to serve its customers in each of its locations. Its segments are AIC focused on the extraction, processing, transportation, and distribution of coal for a variety of industries, with a focus on metallurgical quality coal to the steel industry; RLMT; and EMC.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.